Although API-1 is a potential drug candidate for HCC treatment, especially for Pin1-overexpressing and/or ERK-activated HCC, its clinical application is hampered by its low aqueous solubility and instability under acidic condition, leading to the poor in vivo bioavailability and attenuated therapeutic effects. This evidence concerns the gene PIN1 and hepatocellular carcinoma.